New York-based Anavex Life Sciences announced positive topline results from the company’s Phase III AVATAR trial of Anavex 2-73 (blarcamesione) in adult female patients with Rett syndrome.
Sierra Oncology shared positive topline results from the company’s study on the effectiveness of momelotinib to treat patients with myelofibrosis.
The U.S. Food and Drug Administration approved AbbVie’s Skyrizi (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints and impacts 30 percent of patients with psoriasis.
AC Immune’s stock fell 9 percent on the news that the company’s Phase II Lauriet study of the investigational anti-Tau monoclonal antibody semorinemab in mild-to-moderate Alzheimer’s disease (AD) did not meet all endpoints.
Angion Biomedica and Vifor Pharma announced that their Phase III trial on ANG-3777 for renal transplant patients did not meet the study’s primary and secondary endpoints.
Dupixent (dupilumab) scored the blockbuster medicine’s second study win in a week after Regeneron Pharmaceuticals and Sanofi revealed positive results from the second Phase III trial for the treatment of eosinophilic esophagitis (EoE).
Merck on Oct. 25 revealed positive results from two Phase III trials on a potential treatment for adults with HIV-1 infection and are virologically suppressed on different antiretroviral regimens (ART).
Novartis said on Oct. 25 the company’s canakinumab drug failed in another clinical trial, missing targets to improve overall survival rates for lung cancer patients and prevent the progression-free survival of people with the condition.
The latest results from SURPASS-4, the longest and largest completed SURPASS trial to date, showed consistent activity in maintaining A1C and weight control in the almost two years the study ran. SURPASS-4 is part of the Phase III trial evaluating tirzepatide as a potential treatment for type 2 diabetes.
According to a California WARN notice, Sanofi is shuttering Principia Biopharma’s laboratories in San Francisco and laying off about three dozen employees after the Phase III PEGASUS trial failure of rilzabrutinib for pemphigus.